Schizophrenia Study for Participants on Clozapine
SchizophreniaThis study will look at how safe and how well the investigational drug NaBen®, in addition to clozapine, works in improving the symptoms of refractory schizophrenia.
Schizophrenia is a mental disorder consisting of positive symptoms, negative symptoms, and an inability to pay attention or process information clearly. Sodium benzoate has been shown to regulate brain chemicals that may help to improve some of the schizophrenia symptoms.
The active ingredient in the NaBen® tablet is sodium benzoate. Sodium benzoate is naturally found in cranberries, prunes, plums, cinnamon, ripe cloves, and apples.
null
Participation Requirements
-
Sex:
Male, Female -
Eligible Ages:
18 to 55
Participation Criteria
Inclusion Criteria:
Male or female between 18-55 years of age.
Diagnosis of schizophrenia
Receiving clozapine
Has an identified caregiver or support person to assist with completing study rating scales.
Exclusion Criteria:
Serious medical illnesses, epilepsy, head trauma, neurological illness, movement disorders.
Current substance abuse or history in the past 6 months
Certain medications as determined by the research team.
Study Location
University of Calgary
University of CalgaryCalgary, Alberta
Canada
Contact Study Team
- Study Sponsored By
- University of Calgary
- Participants Required
- More Information
- Study ID:
REB17-1845